Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA:688796)

Market Cap	33.43B +928.2%
Revenue (ttm)	1.38B +40.6%
Net Income	173.20M +416.4%
EPS	0.43 +410.2%
Shares Out	n/a
PE Ratio	193.04
Forward PE	102.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,905,166
Average Volume	1,671,579
Open	83.00
Previous Close	82.44
Day's Range	82.99 - 86.24
52-Week Range	48.06 - 86.24
Beta	n/a
RSI	60.03
Earnings Date	Mar 26, 2026

About SHA:688796

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody development, and Innovative drugs development. The Gene-editing services segment provides the customized gene editing services based on animals as well as c...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 1,306
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688796

Financial Performance

In 2025, SHA:688796's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.